Please ensure Javascript is enabled for purposes of website accessibility

Why Constellation Pharmaceuticals Stock Was Crushing It This Week

By Keith Speights - Jun 3, 2021 at 6:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small drugmaker is being acquired by MorphoSys.

What happened

The stock of Constellation Pharmaceuticals (CNST) was absolutely crushing it this week, up 70.6% as of the market close on Thursday. The catalyst behind this impressive performance was the announcement on Wednesday that German drugmaker MorphoSys (MOR 1.54%) plans to acquire Constellation for $1.7 billion. 

So what

MorphoSys' cash offer of $34 per share for Constellation represented a premium of nearly 72% over the closing price for the biotech stock at the end of last week. Why was MorphoSys willing to pay up so much? It really wanted Constellation's pipeline programs. MorphoSys CEO Jean-Paul Kress stated, "This transformational acquisition represents a major step forward for MorphoSys as we bolster our position in hematology-oncology."

Two jigsaw puzzle pieces that form part of a $100 bill.

Image source: Getty Images.

Constellation is currently evaluating its leading pipeline candidate, pelabresib, in late-stage clinical studies targeting myelofibrosis, a type of bone marrow cancer. The experimental drug inhibits bromodomain and extra-terminal proteins, which some types of cancer cells use to promote growth.

The company also is evaluating CPI-0209 in a phase 2 clinical study targeting hematological and solid tumors. CPI-0209 inhibits EZH2, an enzyme that can promote the growth of certain cancer cells as well as suppress anti-tumor responses.

Now what

MorphoSys' acquisition of Constellation is expected to close in the third quarter of this year. In the meantime, Constellation anticipates providing clinical updates from its late-stage study of pelabresib this summer. An update on the monotherapy cohorts from the phase 2 study of CPI-0209 is expected by the end of the year. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Constellation Pharmaceuticals, Inc. Stock Quote
Constellation Pharmaceuticals, Inc.
MorphoSys AG Stock Quote
MorphoSys AG
$5.92 (1.54%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.